Article Dans Une Revue OncoImmunology Année : 2024

RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome

Résumé

Apoptosis, necroptosis and pro-inflammatory NF-κB-dependent signaling are repressed by receptorinteracting serine/threonine-protein kinase 1 (RIPK1). A recent paper in Immunity describes a small molecule inducing the proteolytic degradation of RIPK1. In preclinical experiments, this RIPK1 inhibitor improved the anticancer efficacy of radiotherapy, immunotherapy (with PD-1 blockade) and radioimmunotherapy (with CTLA-4 blockade).
Fichier principal
Vignette du fichier
39585102.pdf (893.57 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04889551 , version 1 (15-01-2025)

Licence

Identifiants

Citer

Jonathan G Pol, Andrea Checcoli, Manuela Lizarralde-Guerrero, Guido Kroemer. RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome. OncoImmunology, 2024, 13, ⟨10.1080/2162402x.2024.2425465⟩. ⟨hal-04889551⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More